REG - LungLife AI, INC - Admission of New Shares & PDMR Dealing
22/03/2024 08:30
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240322:nRSV9540Ha&default-theme=true
RNS Number : 9540H LungLife AI, INC 22 March 2024
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH
AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR
DISTRIBUTION WOULD BE UNLAWFUL. FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION
PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION.
22 March 2024
LungLife AI, Inc.
(the "Company" or "LungLife")
Admission of New Shares
and
PDMR Dealing
LungLife AI, Inc. (AIM: LLAI), a developer of clinical diagnostic solutions
for the early detection of lung cancer, announces that, further to the Company
announcements on 4 March 2025, 5 March 2024 and 21 March 2024, 5,172,621 new
shares of common stock have been admitted to trading on AIM under the ticker
symbol LLA and ISIN USU5500L1128 in connection with the Fundraising.
The Company also announces that it has been notified of transactions in the
Company's Common Shares by directors in connection with the Fundraising, as
detailed in the Appendix to the announcement.
The Company's total issued share capital now consists of 30,658,603 Common
Shares of US$0.0001 each with one voting right per Common Share. There are no
Common Shares held in treasury. The total number of voting rights in the
Company is therefore 30,658,603. This number may be used by shareholders as
the denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in the
Company.
Unless otherwise defined in this announcement, capitalised terms used in this
announcement shall have the same meanings as defined in the Company's
announcement of 4 March 2024.
For further information please contact:
LungLife AI, Inc. www.lunglifeai.com (https://www.lunglifeai.com/)
Paul Pagano, CEO Via Walbrook PR
David Anderson, CFO
Investec Bank plc (Nominated Adviser & Joint Broker) Tel: +44 (0)20 7597 5970
Virginia Bull / Cameron MacRitchie / Lydia Zychowska
Goodbody Stockbrokers UC (Joint Broker) Tel: +44 (0)20 3841 6202
Tom Nicholson / Cameron Duncan / William Hall
Walbrook PR Limited Tel: +44 (0)20 7933 8780
Paul McManus / Alice Woodings / Phillip Marriage or LungLifeAI@walbrookpr.com (mailto:LungLifeAI@walbrookpr.com)
About LungLife
LungLife AI is a developer of clinical diagnostic solutions designed to make a
significant impact in the early detection of lung cancer, the deadliest cancer
globally. Using a minimally invasive blood draw, the Company's LungLB® test
is designed to deliver additional information to clinicians who are evaluating
indeterminate lung nodules. For more information visit www.lunglifeai.com
(http://www.lunglifeai.com)
APPENDIX
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Paul Pagano
2 Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification/amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name LungLife AI, Inc.
b) LEI 549300VBVDIF0Y3OVI38
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Common shares of US$0.0001 each
Identification code ISIN: USU5500L1128
b) Nature of the transaction Participation in Fundraising
c) Price(s) and volume(s) Price(s) Volume(s)
35p 14,285
d) Aggregated information
- Aggregated volume N/A
- Price N/A
e) Date of the transaction 22 March 2024
f) Place of the transaction Outside a Trading Venue
d)
Aggregated information
- Aggregated volume
- Price
N/A
N/A
e)
Date of the transaction
22 March 2024
f)
Place of the transaction
Outside a Trading Venue
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name David Anderson
2 Reason for the notification
a) Position/status Chief Financial Officer
b) Initial notification/amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name LungLife AI, Inc.
b) LEI 549300VBVDIF0Y3OVI38
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Common shares of US$0.0001 each
Identification code ISIN: USU5500L1128
b) Nature of the transaction Participation in Fundraising
c) Price(s) and volume(s) Price(s) Volume(s)
35p 14,285
d) Aggregated information
- Aggregated volume N/A
- Price N/A
e) Date of the transaction 22 March 2024
f) Place of the transaction Outside a Trading Venue
d)
Aggregated information
- Aggregated volume
- Price
N/A
N/A
e)
Date of the transaction
22 March 2024
f)
Place of the transaction
Outside a Trading Venue
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Gordon Roy Davis
2 Reason for the notification
a) Position/status Non-Executive Chairman
b) Initial notification/amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name LungLife AI, Inc.
b) LEI 549300VBVDIF0Y3OVI38
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Common shares of US$0.0001 each
Identification code ISIN: USU5500L1128
b) Nature of the transaction Participation in Fundraising
c) Price(s) and volume(s) Price(s) Volume(s)
35p 28,571
d) Aggregated information
- Aggregated volume N/A
- Price N/A
e) Date of the transaction 22 March 2024
f) Place of the transaction Outside a Trading Venue
d)
Aggregated information
- Aggregated volume
- Price
N/A
N/A
e)
Date of the transaction
22 March 2024
f)
Place of the transaction
Outside a Trading Venue
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Andrew Boteler
2 Reason for the notification
a) Position/status Non-Executive Director
b) Initial notification/amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name LungLife AI, Inc.
b) LEI 549300VBVDIF0Y3OVI38
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Common shares of US$0.0001 each
Identification code ISIN: USU5500L1128
b) Nature of the transaction Participation in Fundraising
c) Price(s) and volume(s) Price(s) Volume(s)
35p 28,571
d) Aggregated information
- Aggregated volume N/A
- Price N/A
e) Date of the transaction 22 March 2024
f) Place of the transaction Outside a Trading Venue
d)
Aggregated information
- Aggregated volume
- Price
N/A
N/A
e)
Date of the transaction
22 March 2024
f)
Place of the transaction
Outside a Trading Venue
IMPORTANT NOTICES
THIS ANNOUNCEMENT, INCLUDING THE APPENDICES AND THE INFORMATION CONTAINED IN
THEM, IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE, TRANSMISSION,
FORWARDING OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR
INTO THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS, ANY STATE
OF THE UNITED STATES OR THE DISTRICT OF COLUMBIA (COLLECTIVELY, THE "UNITED
STATES"), AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION
IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL. FURTHER,
THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF
SECURITIES IN ANY JURISDICTION.
The securities referred to herein have not been and will not be registered
under the US Securities Act of 1933, as amended (the "Securities Act"), or
with any securities regulatory authority of any State or other jurisdiction of
the United States, and may not be offered, sold or transferred, directly or
indirectly, in or into the United States, or to or for the account or benefit
of US persons (as defined in Regulation S under the Securities Act
("Regulation S")), except pursuant to an exemption from, or in a transaction
not subject to, the registration requirements of the Securities Act and in
compliance with the securities laws of any State or any other jurisdiction of
the United States.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END ALSFIFLTVTIFFISRecent news on LungLife AI
See all newsREG - LungLife AI, INC - Block Listing Six Monthly Return
AnnouncementREG - LungLife AI, INC - Holding(s) in Company
AnnouncementREG - LungLife AI, INC - Publication of Annual Report and Notice of AGM
AnnouncementRCS - LungLife AI, INC - Presentation at NCI's EDRN Meeting
AnnouncementREG - LungLife AI, INC - Preliminary Audited Results
Announcement